GCS INSTITUT DE CANCEROLOGIE STRASBOURG EUROPE

Their core work

GCS Institut de Cancérologie Strasbourg Europe (ICANS) is a comprehensive cancer centre in Alsace, France, combining clinical oncology, translational research, and patient care under one roof. Their H2020 work spans two distinct but complementary fronts: epidemiological research into rare digestive cancers (gallbladder cancer) with a focus on risk stratification and early detection, and experimental cancer immunotherapy through theranostic immune cell approaches. They bring clinical patient cohorts, biobank access, and translational research infrastructure to international consortia. Their institutional mandate bridges bench-to-bedside cancer research, making them a clinical anchor partner in multi-country oncology projects.

What they specialise in

How they've shifted over time

In their first H2020 engagement (2019), ICANS contributed to population-level cancer research: risk prediction models, biomarker identification, and health access issues for rare digestive cancers across European and Latin American cohorts. By 2021, their second project shifted toward experimental immunotherapy — theranostic immune cells — which is a markedly different register, moving from epidemiology and prevention into therapeutic mechanism and precision treatment delivery. The absence of keywords for the theranoimmuno project in available data limits certainty, but the ERC Starting Grant format (typically PI-driven experimental research) suggests the 2021 project is led by a researcher within or affiliated with the centre, indicating growing in-house experimental oncology capability.

ICANS appears to be broadening from population-level cancer epidemiology toward experimental immunotherapy and theranostics, suggesting future collaborations may sit at the intersection of immuno-oncology, targeted therapy, and diagnostic-therapeutic integration.

How they like to work

ICANS has participated exclusively as a consortium partner — never as coordinator — across both H2020 projects, which is consistent with a clinical research centre that brings specialised patient cohorts and translational infrastructure rather than project management leadership. With 18 unique partners across 9 countries spread over just two projects, they engage in relatively broad, internationally diverse consortia rather than small bilateral arrangements. This suggests they are sought out as a clinical or translational node within larger research networks, rather than driving research agendas themselves.

ICANS has built connections with 18 unique consortium partners across 9 countries through just two projects, reflecting a genuinely international network for an organisation of this size. Their EULAT project explicitly bridges Europe and Latin America (Andean countries), giving them an unusual cross-continental reach in oncology research.

What sets them apart

ICANS is one of the few French comprehensive cancer centres with documented H2020 engagement in both rare digestive cancer epidemiology and cutting-edge cancer immunotherapy, covering the full prevention-to-treatment spectrum. Their geographic bridging role between European and Latin American oncology cohorts is rare and valuable for researchers who need population diversity in cancer risk studies. For a consortium builder in oncology, ICANS offers access to a clinical patient base, translational research capacity, and cross-continental collaborative experience that a pure academic laboratory cannot provide.

Highlights from their portfolio

• theranoimmuno
  The largest single funding award to ICANS (€812,912 via ERC Starting Grant), this project signals an emerging in-house experimental immunotherapy capability beyond the centre's traditional clinical focus.
• EULAT Eradicate GBC
  A rare European-Latin American consortium targeting gallbladder cancer — one of the most neglected digestive cancers — giving ICANS a distinctive niche in global cancer epidemiology and cross-continental cohort research.